Literature DB >> 18922926

Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Jianghua Wang1, Yi Cai, Wendong Yu, Chengxi Ren, David M Spencer, Michael Ittmann.   

Abstract

TMPRSS2/ERG gene fusions are found in the majority of prostate cancers; however, there is significant heterogeneity in the 5' region of the alternatively spliced fusion gene transcripts. We have found that there is also significant heterogeneity within the coding exons as well. There is variable inclusion of a 72-bp exon and other novel alternatively spliced isoforms. To assess the biological significance of these alternatively spliced transcripts, we expressed various transcripts in primary prostatic epithelial cells (PrEC) and in an immortalized PrEC line, PNT1a. The fusion gene transcripts promoted proliferation, invasion, and motility with variable activities that depended on the structure of the 5' region encoding the TMPRSS2/ERG fusion and the presence of the 72-bp exon. Cotransfection of different isoforms further enhanced biological activity, mimicking the situation in vivo, in which multiple isoforms are expressed. Finally, knockdown of the fusion gene in VCaP cells resulted in inhibition of proliferation in vitro and tumor progression in an in vivo orthotopic mice model. Our results indicate that TMPRSS2/ERG fusion isoforms have variable biological activities promoting tumor initiation and progression and are consistent with our previous clinical observations indicating that certain TMPRSS2/ERG fusion isoforms are significantly correlated with more aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922926      PMCID: PMC2597580          DOI: 10.1158/0008-5472.CAN-08-1147

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis.

Authors:  Feng Yang; Jennifer A Tuxhorn; Steven J Ressler; Stephanie J McAlhany; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

Review 3.  ETS transcription factors and their emerging roles in human cancer.

Authors:  Arun Seth; Dennis K Watson
Journal:  Eur J Cancer       Date:  2005-10-06       Impact factor: 9.162

4.  Constitutive expression of FGF2/bFGF in non-tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype.

Authors:  F Ropiquet; P Berthon; J M Villette; G Le Brun; N J Maitland; O Cussenot; J Fiet
Journal:  Int J Cancer       Date:  1997-07-29       Impact factor: 7.396

5.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

Authors:  B Lin; C Ferguson; J T White; S Wang; R Vessella; L D True; L Hood; P S Nelson
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 6.  Recurrent chromosome aberrations in cancer.

Authors:  F Mitelman
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

7.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.

Authors:  Jianghua Wang; David W Stockton; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

9.  Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.

Authors:  Dinesh S Rao; Sarah V Bradley; Priti D Kumar; Teresa S Hyun; Djenann Saint-Dic; Katherine Oravecz-Wilson; Celina G Kleer; Theodora S Ross
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

10.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Authors:  C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

View more
  93 in total

1.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

2.  Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.

Authors:  Longjiang Shao; Nermin Kahraman; Ge Yan; Jianghua Wang; Bulent Ozpolat; Michael Ittmann
Journal:  Prostate       Date:  2019-10-15       Impact factor: 4.104

3.  ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Authors:  Rohit Bose; Wouter R Karthaus; Joshua Armenia; Wassim Abida; Phillip J Iaquinta; Zeda Zhang; John Wongvipat; Elizabeth V Wasmuth; Neel Shah; Patrick S Sullivan; Michael G Doran; Ping Wang; Anna Patruno; Yilin Zhao; Deyou Zheng; Nikolaus Schultz; Charles L Sawyers
Journal:  Nature       Date:  2017-06-14       Impact factor: 49.962

4.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

5.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Authors:  Veit J Scheble; Martin Braun; Rameen Beroukhim; Craig H Mermel; Christian Ruiz; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; Markus Reischl; Rainer Kuefer; David Schilling; Falko Fend; Glen Kristiansen; Matthew Meyerson; Mark A Rubin; Lukas Bubendorf; Sven Perner
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

6.  Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Authors:  Yiwei Li; Dejuan Kong; Zhiwei Wang; Aamir Ahmad; Bin Bao; Subhash Padhye; Fazlul H Sarkar
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

10.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.